

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
Signum Biosciences, Inc.	03/31/2012
RECEIVING PARTY DATA	
Name:	Argyle Therapeutics, Inc.
Street Address:	7 Deer Park Drive
City:	Monmouth Junction
State/Country:	NEW JERSEY
Postal Code:	08852
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	12945813
Application Number:	11151174
Application Number:	12616781
Application Number:	12326746
Application Number:	12690906
CORRESPONDENCE DATA	
Fax Number:	(732)393-1901
Phone:	7328390415
Email:	nmartiak@sorinroyercooper.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Nichole E. Martiak
Address Line 1:	Two Tower Center Boulevard, 24th Floor
Address Line 2:	Sorin Royer Cooper LLC
Address Line 4:	East Brunswick, NEW JERSEY 08816
ATTORNEY DOCKET NUMBER:	1356-1 SIGNUM

OP \$200.00 12945813

NAME OF SUBMITTER:

Nichole E. Martiak

Total Attachments: 2

source=00056731#page1.tif

source=00056731#page2.tif

CONFIRMATORY PATENT LICENSE

Date: March 31, 2012

Parties:

- (1) "The Licensors": Signum Biosciences, Inc., having its registered office at 7 Deer Park Drive, Monmouth Junction, New Jersey 08852.
- (2) "The Licensee": Argyle Therapeutics, Inc., having its registered office at 7 Deer Park Drive, Monmouth Junction, New Jersey 08852.

Recitals:

By an Agreement (the "Main Agreement") dated March 31, 2012 and made between the Licensors and the Licensee, the Licensors agreed for the consideration therein contained inter alia to grant to the Licensee a license under the Licensed Patents (as that term is defined in the Main Agreement and as shown in the attached Exhibit A) being this License.

Operative provisions:

1. IN pursuance of the Main Agreement and for the consideration referred to in the Main Agreement the Licensors hereby grants to the Licensee the exclusive license from the 31st day of March, 2012 to use the Licensed Intellectual Property (as defined in the Main Agreement) subject to the provisions of the Main Agreement.
2. SUBJECT as provided in the Main Agreement this License shall terminate without notice in the event of the termination for any reason of the Main Agreement.

WITNESS of which this Agreement has been executed as a deed and delivered the day and year first above written.

EXECUTED as a Deed by:
Signum Biosciences, Inc.


Maxwell Stock, Chief Executive Officer

EXECUTED as a Deed by:
Argyle Therapeutics, Inc.


Maxwell Stock, Chief Executive Officer

EXHIBIT A – LICENSED PATENTS

Patent Family (Countries)	Publication No. (Effective Filing Date)	Claim (Lead Compound)	Status
<u>AFC Analogs (Rando)</u> (US Patent Exclusively licensed from Harvard U.)	US 5,202,456 (1991)	Compound, Compositions and systemic use in cancer treatment (AFC Methyl ester; AGGC, AGC)	AWARDED (Expires Apr 2011)
<u>Topical Arazine</u> (US, AU, BR, CA, CN, EP, IN, JP, MX, SG)	US 2005-0277694; WO 2006/135894 (2005)	Topical Composition and derm use (SIG980 — ARAZINE)	Pending
<u>Isoprenyl Compounds</u> (US, PCT)	US 2010-0184768; WO 2010/056778 (2009)	Compound, Compositions, and use (systemic and topical inflammation) (SIG990; SIG1273 and others)	Pending
<u>Acid Mimics</u> (US, AU, BR, CA, CN, EP, JP)	US 2009-0170917; WO 2009/073665 (2008)	Compound, composition and use (systemic and topical) (SIG1074; SIG1071)	Pending
<u>Acetyl Group Mimics</u> (US, AU, BR, CA, CN, EP, JP)	WO/2009/102997 (2009)	Compound, Compositions, and use (systemic and topical inflammation) (SIG1078; SIG1066; SIG1064; SIG1084; SIG1133)	Pending
<u>Lipidated Peptides</u> (US, JP, CN)	WO 2009/108713 (2009)	Formulation, process and derm use	Pending
<u>AFC and Analog Complexes</u> (US, PCT)	US 2010/0247461 WO2010/090845 (2010)	AFC complexes; compositions and use (systemic and topical inflammation)	Pending
<u>Antibacterial and Acne Use</u> (US, PCT)	*US Application No. 12/945,813 *PCT/US2010/56624 (2010)	Anti-bacterial and anti-inflammatory properties and use in treatment of acne and other bacterial conditions — broad classes of GPMs (SIG990; SIG1273 and others)	Pending
<u>Improved AFC Manufacturing Process</u> (US)	US 2009-0192332 (2009)	Improved manufacturing process of AFC	Pending

00051982.v1